AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Orexo

Declaration of Voting Results & Voting Rights Announcements Aug 31, 2009

3093_rns_2009-08-31_4cab0901-3605-4ba8-b10f-f915cc36e687.pdf

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

Press release, August 31, 2009

New number of shares and votes in Orexo AB (publ)

The total number of shares and votes in Orexo AB (publ) as per August 31, 2009 amounts to 23,401,252. The increase in the number of shares and votes results from the second installment of Orexo's acquisition of PharmaKodex Ltd which was announced on August 21, 2009.

For further information please contact:

Johan Andersson, IR-Manager Tel: +46 (0)702 100 451 E-mail: [email protected]

About Orexo

Orexo is a pharmaceutical company focusing on developing treatments for pain and inflammation. The company has four products on the market as well as a project portfolio in late stages of development. Sales and product development are mainly carried out through worldwide partnership agreements with larger pharmaceutical companies. Orexo has 128 employees, and has its head office located in Uppsala, Sweden. More information can be found at www.orexo.com.

Note:

This is information that Orexo AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act and/or the Swedish Securities Markets Act. The information was provided for public release on August 31, 2009 at 17:00 CET.

WEB www.orexo.com POST Orexo AB PHONE $+46$ (o) $18$ 780 88 00 CORP. REG. NO. 556500-0600
E-MAIL $info@$ orexo.com BOX 303 FAX +46 (0)18 780 88 88 Uppsala
se-751 o5 Uppsala +46 (0)18 780 89 99 Solna
Sweden

Talk to a Data Expert

Have a question? We'll get back to you promptly.